With the expected changes in demographics over the next 10-15 years, there is a growing need to increase and accelerate the development of safe and effective therapies for eye disorders. Charles River has the necessary understanding of eye-related diseases and conditions as well as the technical ability and experience to guide your new ocular drugs and treatments through the development process as efficiently as possible.
Common Ocular Therapeutic Targets
- Age-related macular degeneration (wet/dry)
|
- Glaucoma (IOP control and/or neuroprotection)
|
|
|
|
|
|
|
|
|
|
- Other retinal degenerative conditions
|
|
We offer you an integrated approach to ophthalmology research. Compounds or implantable devices intended for ocular treatment can be assessed for efficacy, safety and toxicity. Ocular effects of compounds administered by other routes, such as oral, can also be characterized. These studies can be conducted under Good Laboratory Practice (GLP) conditions either as stand-alone studies or as part of general and specialty toxicology programs. Non-GLP pilot or proof-of-concept studies are also available for your early research needs.
To learn more about services and ocular animal models to support your ophthalmic drug discovery, click here to contact an expert.